Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies
Open Access
- 1 September 2021
- journal article
- review article
- Published by Taylor & Francis Ltd in Vascular Health and Risk Management
- Vol. ume 17, 527-542
- https://doi.org/10.2147/vhrm.s266244
Abstract
Lipoprotein(a) forms a subfraction of the lipid profile and is characterized by the addition of apolipprotein(a) (apo(a)) to apoB100 derived particles. Its levels are mostly genetically determined inversely related to the number of protein domain (kringle) repeats in apo(a). In epidemiological studies, it shows consistent association with cardiovascular disease (CVD) and most recently with extent of aortic stenosis. Issues with standardizing the measurement of Lp(a) are being resolved and consensus statements favor its measurement in patients at high risk of, or with family histories of CVD events. Major lipid-lowering therapies such as statin, fibrates, and ezetimibe have little effect on Lp(a) levels. Therapies such as niacin or cholesterol ester transfer protein (CETP) inhibitors lower Lp(a) as well as reducing other lipid-related risk factors but have failed to clearly reduce CVD events. Proprotein convertase subtilisin kexin-9 (PCSK9) inhibitors reduce cholesterol and Lp(a) as well as reducing CVD events. New antisense therapies specifically targeting apo(a) and hence Lp(a) have greater and more specific effects and will help clarify the extent to which intervention in Lp(a) levels will reduce CVD events.Keywords
This publication has 119 references indexed in Scilit:
- Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring StudyJournal of Lipid Research, 2011
- Lipoprotein(a) as a cardiovascular risk factor: current statusEuropean Heart Journal, 2010
- Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapyJournal of Lipid Research, 2010
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular MortalityJAMA, 2009
- Relationship of Oxidized Phospholipids on Apolipoprotein B-100 Particles to Race/Ethnicity, Apolipoprotein(a) Isoform Size, and Cardiovascular Risk FactorsCirculation, 2009
- The role of oxidized phospholipids in atherosclerosisJournal of Lipid Research, 2009
- Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic MiceCirculation, 2008
- Three single-nucleotide polymorphisms in LPA account for most of the increase in lipoprotein(a) level elevation in African Americans compared with European AmericansJournal of Medical Genetics, 2006
- Lipoprotein(a) and Incident Ischemic StrokeStroke, 2006
- Protein composition of Lp(a) lipoprotein from human plasmaFEBS Letters, 1983